Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2014
10/02/2014WO2014155332A1 Use of 25-hydroxyvitamin d3 to enhance executive functions
10/02/2014WO2014155301A1 Substituted bicyclic compounds as inhibitors of ezh2
10/02/2014WO2014155261A1 Microencapsulation of oxygen liberating reactants
10/02/2014WO2014155189A1 Neuroprotective effect of carotenoids in brain
10/02/2014WO2014155186A1 Food supplement for people with down syndrome, autism spectrum disorder and/or attention deficit disorder with or without hyperactivity
10/02/2014WO2014155184A1 Treatment for parkinson's disease
10/02/2014WO2014155146A1 Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
10/02/2014WO2014155145A1 Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
10/02/2014WO2014155144A1 Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
10/02/2014WO2014155142A1 Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
10/02/2014WO2014155138A1 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
10/02/2014WO2014155135A1 Methods for the treatment of autoimmune diseases
10/02/2014WO2014155111A1 Skincare compositions
10/02/2014WO2014155103A1 Taurine compositions suitable for inhalation
10/02/2014WO2014155074A1 Composition
10/02/2014WO2014155056A1 A galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing
10/02/2014WO2014154927A1 Use of the inhibitor of steroid sulfatases stx64 for treating aging
10/02/2014WO2014154925A1 Neurogenic compounds comprising melatonin and the efficacy thereof in in vivo experiments for use in the treatment of diseases of the nervous system
10/02/2014WO2014154921A1 Method for the synthesis of homologous compounds of azanucleosides
10/02/2014WO2014154899A1 Use of a macrocyclic lactone for treating a complication from a papillomavirus infection
10/02/2014WO2014154897A1 NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
10/02/2014WO2014154896A1 NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
10/02/2014WO2014154895A1 NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
10/02/2014WO2014154859A1 Macrocyclic deaza-purinones for the treatment of viral infections
10/02/2014WO2014154845A1 Pharmaceutically acceptable amine salts of pitavastatin
10/02/2014WO2014154843A1 Modified tgf-beta2 oligonucleotides
10/02/2014WO2014154797A1 Fe(iii) complexes for treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
10/02/2014WO2014154796A1 Compositions comprising complexes of proanthocyanidins with vegetable proteins
10/02/2014WO2014154794A1 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
10/02/2014WO2014154762A1 Dihydroquinazolinone analogues as brd4 inhibitors
10/02/2014WO2014154760A1 Indolinone analogues as brd4 inhibitors
10/02/2014WO2014154747A1 Extraction of tramadol from nauclea latifolia smith
10/02/2014WO2014154727A1 Biaryl-propionic acid derivatives and their use as pharmaceuticals
10/02/2014WO2014154726A1 Biaryl-propionic acid derivatives and their use as pharmaceuticals
10/02/2014WO2014154725A1 Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
10/02/2014WO2014154723A1 Novel pyrrole derivatives for the treatment of cancer
10/02/2014WO2014154683A1 Pharmaceutical formulation comprising phosphatidylcholine for the treatment of ulcerative colitis
10/02/2014WO2014154643A1 Extended release formulations of metformin
10/02/2014WO2014154640A1 Controlled-release formulations comprising metformin and gliclazide
10/02/2014WO2014154612A1 Novel pyridine derivatives
10/02/2014WO2014154586A1 Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)
10/02/2014WO2014154537A1 Polysialic acid and use for treatment of neurodegenerative and neuroinflammatory diseases
10/02/2014WO2014154179A1 2β,3α,5α-TRIHYDROXY-ANDROST-6-ONE AND PREPARATION METHODS AND USE THEREOF
10/02/2014WO2014154173A1 Anti-angiogenic compound
10/02/2014WO2014154168A1 Bicyclic substituted pyrimidine pde-5 inhibitor prodrug
10/02/2014WO2014154131A1 Caffeoyl substituted pentacyclic triterpene derivative and use thereof
10/02/2014WO2014154122A1 Bicyclol amino-acid ester, preparation method for same, and application thereof
10/02/2014WO2014154117A1 Isothiocyanate, preparation method therefor, and use against cancer
10/02/2014WO2014154026A1 PI3K AND/OR mTOR INHIBITOR PRODRUG
10/02/2014WO2014154025A1 Application of a flavonoid in pharmaceutical preparation
10/02/2014WO2014153995A1 Low molecular weight glycosaminoglycan derivative, pharmaceutical composition thereof, preparation method therefor and use thereof
10/02/2014WO2014153919A1 Use of adenosine and derivatives thereof in prevention and treatment of drug-induced liver injury
10/02/2014WO2014153643A1 Compositions and methods for use thereof in the treatment of aniridia
10/02/2014WO2014153636A1 Method for improving the efficacy of a survivin vaccine in the treatment of cancer
10/02/2014WO2014153624A1 Antibacterial compounds
10/02/2014US20140296567 3-hydroxyanthranilic acid (3-haa) therapy for prevention and treatment of hyperlipidemia and its cardiovasular complications
10/02/2014US20140296543 Prenylflavanone compounds for modulating diabetes
10/02/2014US20140296541 Orthoester compound
10/02/2014US20140296513 Novel therapeutic use of p75 receptor antagonists
10/02/2014US20140296502 Antisense design
10/02/2014US20140296498 Tiacumicin Production
10/02/2014US20140296478 Method for selecting a candidate drug compound
10/02/2014US20140296351 Pharmaceutical formulation
10/02/2014US20140296348 Ophthalmological aqueous composition
10/02/2014US20140296347 Method of treating onychomycosis
10/02/2014US20140296345 Method of enhancing hair growth
10/02/2014US20140296342 Pharmaceutical Formulation Comprising NSAID And Cyclodextrin
10/02/2014US20140296341 Formulations based on solid dispersions
10/02/2014US20140296340 Combination/association of adapalene and benxoyl peroxide for treating acne lesions
10/02/2014US20140296338 Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
10/02/2014US20140296337 Cns modulators
10/02/2014US20140296336 Solid retard formulations based on solid dispersions
10/02/2014US20140296333 COMPOSITION OF THE TREATMENT OF VASCULAR DISEASES OR KCa3.1 CHANNEL-MEDIATED DISEASES COMPRISING MODAFINIL OR DERIVATIVES THEREOF
10/02/2014US20140296332 Treatment of circadian rhythm disorders
10/02/2014US20140296331 Treatment of circadian rhythm disorders
10/02/2014US20140296330 Treatment of circadian rhythm disorders
10/02/2014US20140296329 Phytoestrogen product of red clover and pharmaceutical uses thereof
10/02/2014US20140296328 High concentration olopatadine ophthalmic composition
10/02/2014US20140296326 Epidermal growth factor receptor (egfr) and methods of use in adenoviral-associated virus type 6 (aav6) transduction
10/02/2014US20140296319 Composition For Promoting Apoptosis Or Inhibiting Cell Growth, Comprising Epstein-Barr Virus Microrna
10/02/2014US20140296314 Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine
10/02/2014US20140296313 (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators
10/02/2014US20140296312 Treatment of breast cancer
10/02/2014US20140296309 Modified release compositions of epalrestat or a derivative thereof and methods for using the same
10/02/2014US20140296305 Use of Quaternary Pyridinium Salts as Vasoprotective Agents
10/02/2014US20140296304 Pharmaceutically Active Disubstituted Pyridine Derivatives
10/02/2014US20140296303 Use of Pyridoxamine to Treat and/or Prevent Disease Processes
10/02/2014US20140296302 Methods For Treating Inflammation
10/02/2014US20140296301 Topical ophthalmological pharmaceutical composition containing regoragenib
10/02/2014US20140296300 Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis
10/02/2014US20140296299 Methods and compositions for locally increasing body fat
10/02/2014US20140296295 2-alkoxy-substituted dicyanopyridines and their use
10/02/2014US20140296293 Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat
10/02/2014US20140296292 Methods and compositions associated with the granulocyte colony-stimulating factor receptor
10/02/2014US20140296290 Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
10/02/2014US20140296282 Compositions of a polyorthoester and an aprotic solvent
10/02/2014US20140296280 Pures-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1h,-5h-benzo[i,j]quinolizine-2- carboxylic acid l-arginine salt tetrahydrate and a process for its preparation
10/02/2014US20140296279 Intravascular delivery of nanoparticle compositions and uses thereof
10/02/2014US20140296278 5-nonyloxytryptamine and related intracellular ph acidifiers for the treatment and prevention of cancer
10/02/2014US20140296277 Pharmaceutical preparation containing oxycodone and naloxone
1 ... 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 ... 7860